269 related articles for article (PubMed ID: 30061744)
1. Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Gross C; Banerjee A; Tiwari D; Longo F; White AR; Allen AG; Schroeder-Carter LM; Krzeski JC; Elsayed NA; Puckett R; Klann E; Rivero RA; Gourley SL; Bassell GJ
Neuropsychopharmacology; 2019 Jan; 44(2):324-333. PubMed ID: 30061744
[TBL] [Abstract][Full Text] [Related]
2. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome.
Gross C; Nakamoto M; Yao X; Chan CB; Yim SY; Ye K; Warren ST; Bassell GJ
J Neurosci; 2010 Aug; 30(32):10624-38. PubMed ID: 20702695
[TBL] [Abstract][Full Text] [Related]
3. Selective role of the catalytic PI3K subunit p110β in impaired higher order cognition in fragile X syndrome.
Gross C; Raj N; Molinaro G; Allen AG; Whyte AJ; Gibson JR; Huber KM; Gourley SL; Bassell GJ
Cell Rep; 2015 May; 11(5):681-8. PubMed ID: 25921527
[TBL] [Abstract][Full Text] [Related]
4. Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110β-selective inhibitor.
Gross C; Bassell GJ
Mol Med; 2012 May; 18(1):336-45. PubMed ID: 22207187
[TBL] [Abstract][Full Text] [Related]
5. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
[TBL] [Abstract][Full Text] [Related]
6. Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.
Kumari D; Bhattacharya A; Nadel J; Moulton K; Zeak NM; Glicksman A; Dobkin C; Brick DJ; Schwartz PH; Smith CB; Klann E; Usdin K
Hum Mutat; 2014 Dec; 35(12):1485-94. PubMed ID: 25224527
[TBL] [Abstract][Full Text] [Related]
7. Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice.
Santini E; Huynh TN; Longo F; Koo SY; Mojica E; D'Andrea L; Bagni C; Klann E
Sci Signal; 2017 Nov; 10(504):. PubMed ID: 29114037
[TBL] [Abstract][Full Text] [Related]
8. Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.
De Rubeis S; Fernández E; Buzzi A; Di Marino D; Bagni C
Adv Exp Med Biol; 2012; 970():517-51. PubMed ID: 22351071
[TBL] [Abstract][Full Text] [Related]
9. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
Bilousova TV; Dansie L; Ngo M; Aye J; Charles JR; Ethell DW; Ethell IM
J Med Genet; 2009 Feb; 46(2):94-102. PubMed ID: 18835858
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.
Franklin AV; King MK; Palomo V; Martinez A; McMahon LL; Jope RS
Biol Psychiatry; 2014 Feb; 75(3):198-206. PubMed ID: 24041505
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.
Berry-Kravis E
Pediatr Neurol; 2014 Apr; 50(4):297-302. PubMed ID: 24518745
[TBL] [Abstract][Full Text] [Related]
12. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
[TBL] [Abstract][Full Text] [Related]
13. Carbamazepine Restores Neuronal Signaling, Protein Synthesis, and Cognitive Function in a Mouse Model of Fragile X Syndrome.
Ding Q; Zhang F; Feng Y; Wang H
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297570
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome signature analysis repurposes trifluoperazine for the treatment of fragile X syndrome in mouse model.
Ding Q; Sethna F; Wu XT; Miao Z; Chen P; Zhang Y; Xiao H; Feng W; Feng Y; Li X; Wang H
Commun Biol; 2020 Mar; 3(1):127. PubMed ID: 32179850
[TBL] [Abstract][Full Text] [Related]
15. Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.
Liu ZH; Chuang DM; Smith CB
Int J Neuropsychopharmacol; 2011 Jun; 14(5):618-30. PubMed ID: 20497624
[TBL] [Abstract][Full Text] [Related]
16. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
[TBL] [Abstract][Full Text] [Related]
17. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.
Dolan BM; Duron SG; Campbell DA; Vollrath B; Shankaranarayana Rao BS; Ko HY; Lin GG; Govindarajan A; Choi SY; Tonegawa S
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5671-6. PubMed ID: 23509247
[TBL] [Abstract][Full Text] [Related]
18. Targeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice.
Bhattacharya A; Mamcarz M; Mullins C; Choudhury A; Boyle RG; Smith DG; Walker DW; Klann E
Neuropsychopharmacology; 2016 Jul; 41(8):1991-2000. PubMed ID: 26708105
[TBL] [Abstract][Full Text] [Related]
19. Increasing our understanding of human cognition through the study of Fragile X Syndrome.
Cook D; Nuro E; Murai KK
Dev Neurobiol; 2014 Feb; 74(2):147-77. PubMed ID: 23723176
[TBL] [Abstract][Full Text] [Related]
20. Astroglial FMRP modulates synaptic signaling and behavior phenotypes in FXS mouse model.
Jin SX; Higashimori H; Schin C; Tamashiro A; Men Y; Chiang MSR; Jarvis R; Cox D; Feig L; Yang Y
Glia; 2021 Mar; 69(3):594-608. PubMed ID: 32970902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
